COMMUNIQUÉS West-GlobeNewswire

Informations sur le nombre total de droits de vote et d'actions
25/08/2026
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 25 aout 2026, 22h30 CET / 16h30 ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
25/08/2026
NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Voting Rights and Shares Capital of the Company
25/08/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 25, 2026 (GLOBE NEWSWIRE [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
25/08/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 25 août 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Nanox to Report Second Quarter 2026 Financial Results on September 9, 2026
25/08/2026
PETACH TIKVA, Israel, Aug. 25, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial [...]
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
25/08/2026
GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option [...]
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
25/08/2026
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being [...]
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
25/08/2026
Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50) [...]
Acquisition of Own Shares
25/08/2026
Mechelen, Belgium; 25 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Incuvate Files Patent Infringement Lawsuit Against Penumbra
25/08/2026
Complaint alleges Penumbra’s THUNDERBOLT™ system infringes five Incuvate patents covering blood-clot detection technology IRVINE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Incuvate, LLC today announced that it has filed [...]
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
25/08/2026
COPENHAGEN, Denmark, August 25, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial [...]
BrewDog cumule les distinctions aux World Beer Awards 2026 et confirme l’excellence de son savoir-faire brassicole
25/08/2026
Les bières Hazy Jane, Wingman et Mackie’s Two Scoops remportent une médaille d’or et le titre de meilleure de leur catégorie en Écosse. Les références Punk IPA, Lost Lager, Black Heart et Mello se distinguent également [...]
Rio Tinto Canada Fund invests $2 million to advance healthcare innovation in Quebec
25/08/2026
Support for two groundbreaking initiatives will accelerate innovation, strengthen patient care and advance research with global impact MONTREAL, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The Rio Tinto Canada Fund is investing $ [...]
Le Fonds Rio Tinto Canada investit 2 millions de dollars pour faire avancer l’innovation en santé au Québec
25/08/2026
Le soutien apporté à deux projets novateurs accélérera l’innovation, renforcera les soins aux patients et fera progresser la recherche, à l’échelle mondiale MONTRÉAL, 25 août 2026 (GLOBE NEWSWIRE) -- Le Fonds Rio Tinto [...]
Nu-Tek BioSciences to Attend BPI East 2026 in Boston, Connecting Animal-Free Culture Media Nutrients with Pharma Customer Growth Strategies
25/08/2026
Nu-Tek will meet with pharmaceutical leadership during BioProcess International East Sept. 22-25 in Boston to discuss 100% animal-origin-free peptones and protein hydrolysates, with a focus on product quality and supply [...]
Mixie Technologies, Inc. (OTC: MIXE) Portfolio Company HoloTwin Unveils TwinRuntime: Enterprise Digital Twins That Run in a Standard Web Browser, No Downloads Required
25/08/2026
Mixie Technologies' flagship portfolio company milestone caps a year that took HoloTwin from a strategic investment, to a CES 2026 award, to HoloTwin 2.0, and now to a browser-native runtime that puts living digital [...]
CVRx Responds to Letter from Pointillist Family Office
25/08/2026
MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
25/08/2026
TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic [...]
Annovis to Host Corporate Update Webinar on September 2, 2026
25/08/2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]

Pages